Anteris Technologies prices $200 million public offering at $5.75 per share

Anteris Technologies Global Corp. (NASDAQ: AVR) announced the pricing of its public offering of 34,782,609 shares of common stock at $5.75 per share. The medical device company expects to raise approximately $200 million in gross proceeds before deducting underwriting discounts and offering expenses.

The offering is expected to close on January 22, 2026, subject to customary closing conditions. The company has granted underwriters a 30-day option to purchase up to an additional 5,217,391 shares at the offering price.

Separately, Anteris entered into a stock purchase agreement with Medtronic plc for a private placement of up to $90 million in shares at the same price as the public offering. The private placement requires Medtronic to purchase between 16% and 19.99% of outstanding shares after the offering. The private placement depends on completion of the public offering, though the public offering does not require the private placement to close.

Anteris plans to use the net proceeds to support its clinical strategy, including ongoing recruitment for the PARADIGM Trial of its DurAVR Transcatheter Heart Valve for patients with severe aortic stenosis. Funds will also support manufacturing expansion, research and development for v2vmedtech, and general corporate purposes.

Barclays, Wells Fargo Securities and Cantor are serving as joint book-running managers for the offering. Wells Fargo Securities is acting as sole placement agent for the Medtronic private placement.

The shares are being offered under a shelf registration statement filed with the Securities and Exchange Commission that became effective on January 8, 2026.

You May Also Be Interested In

• Silence Therapeutics closes $201M public offering of ADSs
• KKR to sell 5 million BridgeBio shares in secondary offering
• Avnet (AVT) files mixed shelf